INVESTOR ALERT: Goldberg Law PC Announces an Investigation of Spectrum Pharmaceuticals, Inc.
September 16 2016 - 7:07PM
Business Wire
Goldberg Law PC announces that it is investigating Spectrum
Pharmaceuticals, Inc. (“Spectrum” or the “Company”) (Nasdaq: SPPI)
concerning possible violations of federal securities laws.
If you purchased or otherwise acquired Spectrum shares and would
like more information regarding the investigation, we advise you to
contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999
Avenue of the Stars Suite 1100, Los Angeles, CA 90067, at
800-977-7401, to discuss your rights without cost to you. You can
also reach us through the firm’s website at
http://www.Goldberglawpc.com, or by email at
info@goldberglawpc.com.
The investigation focuses on a statement by the Company that it
failed to disclose that the Food & Drug Administration advised
it to not submit a New Drug Application for its drug candidate
apaziquone back in December of 2012.
If you have any questions concerning your legal rights, please
immediately contact Goldberg Law PC at 800-977-7401, or visit our
website at http://www.Goldberglawpc.com, or email us at
info@goldberglawpc.com.
Goldberg Law PC represents shareholders around the world and
specializes in securities class actions and shareholder rights
litigation.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160916005873/en/
Goldberg Law PC, Los AngelesMichael Goldberg, Esq.,
800-977-7401Brian Schall, Esq.,
800-977-7401info@goldberglawpc.comhttp://www.Goldberglawpc.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Apr 2023 to Apr 2024